<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib14">
 <element-citation publication-type="journal" id="sref14">
  <person-group person-group-type="author">
   <name>
    <surname>Chen</surname>
    <given-names>C.-N.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>C.P.C.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>K.-K.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>W.-C.</given-names>
   </name>
   <name>
    <surname>Hsieh</surname>
    <given-names>H.-P.</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>P.-H.</given-names>
   </name>
   <name>
    <surname>Hsu</surname>
    <given-names>J.T.-A.</given-names>
   </name>
  </person-group>
  <article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3â€™-digallate (TF3)</article-title>
  <source>Evidence-based Complementary and Alternative Medicine: ECAM</source>
  <volume>2</volume>
  <issue>2</issue>
  <year>2005</year>
  <fpage>209</fpage>
  <lpage>215</lpage>
  <pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id>
  <pub-id pub-id-type="pmid">15937562</pub-id>
 </element-citation>
</ref>
